The Science of Sustained-Release Medications

Sustained release pharmaceutical products became a very useful tool in medical practice, actual and perceived advantages to the patients. Sustained release is also providing promising way to decrease the side effect of drug by preventing the fluctuation of the therapeutic concentration of the drug in the body. Sustained release system are considered a wiser approach for the drug with short half lives and which requires repeated dosing, they are easy to formulate and irrespective of absorption process from gastrointestinal tract after oral administration. Sustained systems include any drug delivery system that achieves slow release of drug over an extended period of time. Now a days as very few drugs are coming out of research and development and already existing drugs are suffering the problem of resistance due to their irritational use specifically in case of drug like antibiotics. The basic rationale of sustained release drug delivery system optimizes of the biopharmaceutical and pharmacokinetic and pharmacodynamics properties of the drug in such a way that utility is maximized, side effect reduced and cure of the disease is achieved. The principle goal of sustained release form is the improvements of drug therapy assessed by the relationship between advantages of the use of sustained release system. This article contains the basic information regarding sustained release formulation and also the different types of the same.

Science ,Sustained, Release , Medications

1. Rout S, Kar D, A brief Review on Modified Release Solid Dosage Form with special reference to Design, International Journal of Research in Ayurveda and Pharmacy, 2011, page no.-1701-1708. [Google Scholar] [Crossref]

2. Punna Rao Ravi, Sidhura Ganga, Design and Study of Lamivudine Oral Controlled Release Tablets. AAPS PharmSciTech, 8(4), 2007, 1-9. [Google Scholar] [Crossref]

3. Wagnaer JG, Biopharmaceutics and pharmacokinetics Org Intelligence publishers, 1971, Page no-148-157. [Google Scholar] [Crossref]

4. Garg S, SharmaS,Gastroretentive Drug delivery system. Businessbriefing, Pharmatech 2003, Page no.-160-162. [Google Scholar] [Crossref]

5. Marc MP,JulieHR,Burnies M Tasosartin, Enolatasosartan and Angiotensin 2 Receptor Blockade; The confounding Role of Protein Binding, The journal of Pharmacology and environmental Therapeutics, 2005, Page no.-649-653. [Google Scholar] [Crossref]

6. Cavillo D, MullolJ, BartaJ, Davila, Jauregui, MontoroJ, Sastre J Valero AL. Comparative pharmacology of the HJ anti Histamine J Investig AllergolClinImmunol 2006;16:3-12. [Google Scholar] [Crossref]

7. Swarbrick J, Boylan J C.Encyclopedia of Pharmaceutical Technology, 2007, Page no.-369-394. [Google Scholar] [Crossref]

8. Lechmen L, Liberman H, The Theory and Practice of Industrial Pharmacy, Sustained release dosage form, Third edition, year-1991, Page no.-430-456 [Google Scholar] [Crossref]

9. Shalin A. Modi, P. D. Gaikwad, V . H. Bankar, S. P. Pawar , Sustained Release Drug Delivery System : A Review, International Journal of Pharma Research and Development, 2(12), 2011,147-160. [Google Scholar] [Crossref]

10. Dinesh Kumar M, Jain DK. Formulation and evaluation of valsartan sustained release matrix tablets. Bull Pharm Res 2014;4:81-5. [Google Scholar] [Crossref]

11. Chandana CH, Ganesh Kumar Y, Vamshi Vishnu Y, Minnu Madhuri M. Metoprolol Succinate SR matrix tablets-formulation development and in vitro evaluation. Int J Pharm Pharm Sci 2014;6:481-6. [Google Scholar] [Crossref]

12. Chaitanya B, Vishnu P, Kiran RS, Naveen Babu K, Vijayavani CH. Formulation and evaluation of sustained release tablets of Vildagliptin. Int J Pharm 2013;3:587-93. [Google Scholar] [Crossref]

13. Punna Rao Ravi, Sidhura Ganga, Design and Study of Lamivudine Oral Controlled Release Tablets. AAPS PharmSciTech, 8(4), 2007, 1-9. [Google Scholar] [Crossref]

14. Alford N Martin, Patrick J. Sinko. Martin’s Physical pharmacy and pharmaceutical sciences, 2006. 27. [Google Scholar] [Crossref]

15. L. Lachman, HA Lieberman, Joseph L Kanig. The theory and practice of Industrial pharmacy, Verghesh publishing house, 3rd edition, 1990; 346. [Google Scholar] [Crossref]

16. Shargel L, Yu ABC. Modified release drug products. In: Applied Biopharmaceutics and Pharmacokinetics. 4th edition, 1999: 169-171. [Google Scholar] [Crossref]

17. Leon S, Susanna W, Andrew BC , “Applied Biopharmaceutics and Pharmacokinetics”, 5th edition McGraw-Hill’s Access Pharmacy, 2004, 17.1-17.9. 30. [Google Scholar] [Crossref]

18. Sayed I. Abdel-Rahman, Gamal MM, El-Badry M, Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets, Saudi Pharmaceutical Journal ,2009 ; 17: 283-288. [Google Scholar] [Crossref]

19. Chandran S, Laila FA and Mantha N, Design and evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics, Indian Journal of Pharmaceutical Sciences, September-October 2008. [Google Scholar] [Crossref]

20. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494. [Google Scholar] [Crossref]

21. mamidala RK, Ramana V, sandeep G, “Factors influencing the design and performance of oral, sustained /controlled Release dosage forms” UPSN,2009,S83-S86. [Google Scholar] [Crossref]

22. Muzib Y.Indira, Padma Sree.Kurri: Formulation and evaluation of gum olibanumbased sustained release matrix hydrochloride. tablets International of Ambroxol Journal of Pharmacy and Pharmaceutical Sciences 2011; 3(2): 195-199. [Google Scholar] [Crossref]

23. Vyas SP, Khar RK. Controlled Drug Delivery: Concepts and Advances. Ist ed. vallabh prakashan, 2002:156-189. 23. Melia CD. Hydrophilic matrix sustained release systems 395- based on polysaccharide carriers. Crit. Rev. Ther. Drug Carrier Sys. [Google Scholar] [Crossref]

24. 1991; 8(4): 421. 24. Aulton Michael .E, The Design and Manufacture of Medicines, Church Hill Living Stone Vol. 3, 2007: 483-494. [Google Scholar] [Crossref]

25. Jantzen GM, Robinson JR, Sustained and controlled-release drug delivery systems, in Banker GS, Rhodes CT (Eds.) Modern Pharmaceutics, Third Edition, Revised and Expanded, Drugs and the Pharmaceutical Sciences, vol 72, Marcell Dekker, Inc. New York, 1995: 575-609. [Google Scholar] [Crossref]

26. Alford N Martin, Patrick J. Sinko. Martin’s Physical pharmacy and pharmaceutical sciences, 2006. [Google Scholar] [Crossref]

27. L. Lachman, HA Lieberman, Joseph L Kanig. The theory and practice of Industrial pharmacy, Verghesh publishing house, 3rd edition, 1990; 346. [Google Scholar] [Crossref]

28. mamidala RK, Ramana V, sandeep G, “Factors influencing the design and performance of oral, sustained /controlled Release dosage forms” UPSN,2009,S83-S86. [Google Scholar] [Crossref]

29. Leon S, Susanna W, Andrew BC , “Applied Biopharmaceutics and Pharmacokinetics”, 5th edition McGraw-Hill’s Access Pharmacy, 2004, 17.1-17.9. [Google Scholar] [Crossref]

30. Sayed I. Abdel-Rahman, Gamal MM, El-Badry M, Preparation and comparative evaluation of sustained release metoclopramide hydrochloride matrix tablets, Saudi Pharmaceutical Journal ,2009 ; 17: 283-288. [Google Scholar] [Crossref]

31. Chandran S, Laila FA and Mantha N, Design and evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics, Indian Journal of Pharmaceutical Sciences, September-October 2008. [Google Scholar] [Crossref]

32. Brahmankar HA, Jaiswal SB. Biopharmaceutics and Pharmacokinetics A Treatise, Vallabh Prakashan, 2000, 348-357 and 337. [Google Scholar] [Crossref]

33. Venkatraman S, Davar A, Chester A, Kleiner L, Wise DL. An overview of controlled release systems, Handbook of Pharmaceutical Controlled Release Technology, New York, Marcel Dekker, Inc.,2000, 431-465. [Google Scholar] [Crossref]

• Development and Evaluation of Floating Alginate Beads of Esomeprazole
• Determination of pKa Value for Ranolazine and Atenolol Using UV Spectroscopy
• Development of Proteomics in Clinical Medicine